PIPERACILLIN AND TAZOBACTAM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Piperacillin And Tazobactam, and when can generic versions of Piperacillin And Tazobactam launch?
Piperacillin And Tazobactam is a drug marketed by Astral, Eugia Pharma, Eugia Pharma Speclts, Fresenius Kabi, Fresenius Kabi Usa, Hospira Inc, Istituto Bio Ita Spa, Provepharm Sas, Sagent Pharms Inc, Sandoz, Shandong, Steriscience, and Wockhardt Bio Ag. and is included in twenty-two NDAs.
The generic ingredient in PIPERACILLIN AND TAZOBACTAM is piperacillin sodium; tazobactam sodium. There are sixteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the piperacillin sodium; tazobactam sodium profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PIPERACILLIN AND TAZOBACTAM?
- What are the global sales for PIPERACILLIN AND TAZOBACTAM?
- What is Average Wholesale Price for PIPERACILLIN AND TAZOBACTAM?
Summary for PIPERACILLIN AND TAZOBACTAM
US Patents: | 0 |
Applicants: | 13 |
NDAs: | 22 |
Finished Product Suppliers / Packagers: | 15 |
Raw Ingredient (Bulk) Api Vendors: | 2 |
Clinical Trials: | 90 |
Formulation / Manufacturing: | see details |
DailyMed Link: | PIPERACILLIN AND TAZOBACTAM at DailyMed |
Recent Clinical Trials for PIPERACILLIN AND TAZOBACTAM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Scandinavian Critical Care Trials Group | Phase 4 |
University Hospital, Rouen | Phase 3 |
Wake Forest University Health Sciences | Phase 4 |
Pharmacology for PIPERACILLIN AND TAZOBACTAM
Drug Class | Penicillin-class Antibacterial beta Lactamase Inhibitor |
Mechanism of Action | beta Lactamase Inhibitors |